SMN2 protein, human; Survival of Motor Neuron 2 Protein; Child; Humans; Infant; Infant, Newborn; Neonatal Screening; Survival of Motor Neuron 2 Protein/genetics; Muscular Atrophy, Spinal/drug therapy; Muscular Atrophy, Spinal/genetics; Spinal Muscular Atrophies of Childhood/drug therapy; Spinal Muscular Atrophies of Childhood/genetics; Muscular Atrophy, Spinal; Spinal Muscular Atrophies of Childhood; Biochemistry, Genetics and Molecular Biology (all); General Biochemistry, Genetics and Molecular Biology; General Medicine
Abstract :
[en] SPR1NT ( NCT03505099 ) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.
Disciplines :
Neurology Pediatrics
Author, co-author :
Strauss, Kevin A ; Clinic for Special Children, Strasburg, PA, USA. kstrauss@clinicforspecialchildren.org ; Penn Medicine-Lancaster General Hospital, Lancaster, PA, USA. kstrauss@clinicforspecialchildren.org ; Departments of Pediatrics and Molecular, Cell & Cancer Biology, University of Massachusetts School of Medicine, Worcester, MA, USA. kstrauss@clinicforspecialchildren.org
Farrar, Michelle A ; Department of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia ; School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia
Muntoni, Francesco; The Dubowitz Neuromuscular Centre, University College London, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK ; National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre, London, UK
Saito, Kayoko ; Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan
Mendell, Jerry R; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA ; Department of Pediatrics and Department of Neurology, The Ohio State University, Columbus, OH, USA
Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; Department of Paediatrics, MDUK Oxford Neuromuscular Centre, Oxford, UK
McMillan, Hugh J ; Departments of Pediatrics, Neurology & Neurosurgery, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
Finkel, Richard S ; Department of Pediatrics, Nemours Children's Hospital, Orlando, FL, USA ; Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA
Swoboda, Kathryn J ; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
Kwon, Jennifer M; Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Zaidman, Craig M; Washington University School of Medicine, St. Louis, MO, USA
Chiriboga, Claudia A; Division of Pediatric Neurology, Columbia University Medical Center, New York, NY, USA
Iannaccone, Susan T ; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA
Krueger, Jena M; Department of Neurology, Helen DeVos Children's Hospital, Grand Rapids, MI, USA
Parsons, Julie A; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
Shieh, Perry B; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Kavanagh, Sarah; Novartis Gene Therapies, Inc., Bannockburn, IL, USA
Tauscher-Wisniewski, Sitra; Novartis Gene Therapies, Inc., Bannockburn, IL, USA
McGill, Bryan E ; Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Macek, Thomas A ; Novartis Gene Therapies, Inc., Bannockburn, IL, USA
The authors wish to thank the investigators, site coordinators and study teams, administrators of newborn screening programs, and most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for BioMedical Research, who provided critical review and input on content related to biodistribution, immune response, and safety; S. P. Reyna, who provided critical review and input on care of patients with SMA; and M. Wolf of Novartis Gene Therapies, who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by M. Heitzer of Kay Square Scientific, and M. Nissen, of Novartis Gene Therapies. This support was funded by Novartis Gene Therapies. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children’s Hospital Network, Children’s Medical Research Institute, and Children’s Cancer Institute, established with the support of the NSW Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications. Novartis Gene Therapies, Inc., sponsored this study.The authors wish to thank the investigators, site coordinators and study teams, administrators of newborn screening programs, and most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for BioMedical Research, who provided critical review and input on content related to biodistribution, immune response, and safety; S. P. Reyna, who provided critical review and input on care of patients with SMA; and M. Wolf of Novartis Gene Therapies, who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by M. Heitzer of Kay Square Scientific, and M. Nissen, of Novartis Gene Therapies. This support was funded by Novartis Gene Therapies. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children’s Hospital Network, Children’s Medical Research Institute, and Children’s Cancer Institute, established with the support of the NSW Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications. Novartis Gene Therapies, Inc., sponsored this study.Novartis Gene Therapies, Inc., sponsored this clinical trial. The authors declare the following competing interests: K.A.S. has received personal compensation from Novartis Gene Therapies, Inc., (formerly AveXis) for serving as an advisory board member and from Biogen for serving as a visiting professor; and has received research support from Novartis Gene Therapies Inc., and Biogen-sponsored clinical trials. M.A.F. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., Biogen, and Roche, and research grants from Biogen. F. M. reports grants and personal fees from Novartis Gene Therapies, Inc., including participation in the STR1VE-EU grant and the SPR1NT study; grants, personal fees, and other (participation in the SHINE clinical trial and principal investigator of the investigator-initiated UK SMA REACH UK registry) from Biogen; and grants and personal fees from Roche, including participation in the JEWELFISH clinical trial of risdiplam and participation in the olesoxime clinical trial, during the conduct of the study. He has received honoraria for scientific advisory boards from Biogen, Novartis, Novartis Gene Therapies, Inc., PTC, Roche, and Sarepta. K. S. has served on advisory boards for Biogen, Novartis Gene Therapies, Inc., Novartis, and Chugai (Roche), and has received research funding from Biogen. J. R. M. has received personal compensation for clinical trial consulting and for serving on scientific advisory boards, as well as research support,from Novartis Gene Therapies, Inc. L.S. has received personal compensation as an advisory committee board member/consultant from Novartis Gene Therapies, Inc., Biogen, Biophytis, Cytokinetics, Dynacure, Roche, Santhera, and Sarepta Therapeutics, and has received research support from Novartis Gene Therapies, Inc., Biogen, Dynacure, and Roche. H. J. M. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., and research funding from Roche. R. S. F. has received personal compensation for consulting for advisory board participation from Novartis Gene Therapies, Inc., Biogen, Roche, and Scholar Rock, and for consulting from Novartis; editorial fees from Elsevier for co-editing a neurology textbook; license fees from the Children’s Hospital of Philadelphia; research funding from Novartis Gene Therapies, Inc., Biogen, Roche/Genentech, and Scholar Rock. K. J. S. has received personal compensation for a speaking engagement from Biogen, and research funding as a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., and Biogen. J. M. K. (Kwon) was her site’s principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Biogen, and Scholar Rock. C. M. Z. has received research support from Biogen. C. A. C. has served on advisory boards for Novartis Gene Therapies, Inc., Genentech, and Roche; served as an educational speaker for Biogen, and has received research funding from Novartis Gene Therapies, Inc., Biogen, and Roche. S. T. I. has received personal compensation for service on advisory boards or consulting from Novartis Gene Therapies, Inc., Biogen, Roche-Genetech, and Sarepta; and research support from Novartis Gene Therapies, Inc., Biogen, Capricor, PTC, Scholar Rock, and Sarepta. J. M. K. (Krueger) is a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Scholar Rock, and Genentech-Roche. J. A. P. has served as an investigator on clinical trials for Biogen, Novartis, PTC Therapeutics, and Scholar Rock, and has served in advisory capacity for Biogen, Scholar Rock, Genentech Roche, and Novartis. P. B. S. has served as a consultant for Alexion, Biogen, Genentech, Novartis Gene Therapies, Inc., and Sarepta, and has served as a speaker for Alexion, Biogen, Genentech, Grifols, Novartis Gene Therapies, Inc., and PTC Therapeutics. S. K. is an employee of Novartis Gene Therapies, Inc., and receives consulting fees from UCB Pharma, Karuna Therapeutics, Worldwide Clinical Trials, CPC Clinical Research, Zosano Pharmaceuticals, PharPoint Research, and Nesos. S. T.-W. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. B.E.M. is an employee of Translational Medicine, Novartis Institutes for BioMedical Research (Cambridge) and owns Novartis stock or other equities. T.A.M. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. Novartis Gene Therapies, Inc., sponsored this study.
Coovert, D. D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205–1214 (1997).
Mailman, M. D. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med. 4, 20–26 (2002).
Calucho, M. et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28, 208–215 (2018).
Thomas, N. H. & Dubowitz, V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul. Disord. 4, 497–502 (1994).
McGrattan, K. E., Graham, R. J., DiDonato, C. J. & Darras, B. T. Dysphagia phenotypes in spinal muscular atrophy: the past, present, and promise for the future. Am. J. Speech Lang. Pathol. 30, 1008–1022 (2021).
Finkel, R. S., Weiner, D. J., Mayer, O. H., McDonough, J. M. & Panitch, H. B. Respiratory muscle function in infants with spinal muscular atrophy type I. Pediatr. Pulmonol. 49, 1234–1242 (2014).
Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810–817 (2014).
Kolb, S. J. et al. Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82, 883–891 (2017).
Ramdas, S. & Servais, L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin. Pharmacother. 21, 307–315 (2020).
Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59–65 (2009).
Thomsen, G. et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat. Med. 27, 1701–1711 (2021).
Day, J. W. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy with two copies of SMN2 (STR1VE): an open-label, single-arm, phase 3 study. Lancet Neurol. 20, 284–293 (2021).
Mercuri, E. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 832–841 (2021).
Weiß, C. et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc. Health 6, 17–27 (2022).
Day, J. W. et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 44, 1109–1119 (2021).
Chand, D. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J. Hepatol. 74, 560–566 (2021).
Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).
Al-Zaidy, S. A. et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J. Neuromuscul. Dis. 6, 307–317 (2019).
Waldrop, M. A. et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 146, e20200729 (2020).
Govoni, A. et al. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol. Neurobiol. 5, 6307–6318 (2018).
Lowes, L. P. et al. Impact of age and motor function in a phase 1/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr. Neurol. 98, 39–45 (2019).
De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842–856 (2019).
Servais, L. et al. RAINBOWFISH: a study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA). Neuromuscul. Disord. 31, S48 (2021).
WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr. Suppl. 450, 86–95 (2006).
Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial. Nat. Med. https://doi.org/10.1038/s41591-022-01867-3 (2022).
Bayley, N. Bayley Scales of Infant and Toddler Development: Administration Manual. 3rd edn (Pearson PsychCorp, 2006).
Mendell, J. R. et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834–841 (2021).
Perez-Garcia, M. J., Kong, L., Sumner, C. J. & Tizzano, E. F. in Spinal Muscular Atrophy: Disease Mechanisms and Therapy (eds Sumner, C. J., Paushkin, S. & Ko, C. P.) 21–42 (Academic Press, 2017).
Harding, B. N. et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J. Neuropathol. Exp. Neurol. 74, 15–24 (2015).
Fidzianska, A. & Rafalowska, J. Motoneuron death in normal and spinal muscular atrophy-affected human fetuses. Acta Neuropathol. 104, 363–368 (2002).
Simic, G. et al. Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig–Hoffmann disease. J. Neuropathol. Exp. Neurol. 59, 398–407 (2000).
Swoboda, K. J. et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. 57, 704–712 (2005).
Audic, F. & Barnerias, C. Spinal muscular atrophy (SMA) type I (Werdnig–Hoffmann disease). Arch. Pediatr. 27, 7S15 (2020).
Amato, A. A. & Ropper, A. H. Sensoryganglionopathy. N. Engl. J. Med. 383, 1657–1662 (2020).
Mueller, C. et al. SOD1 suppression with adeno-associated virus and microrna in familial ALS. N. Engl. J. Med. 383, 151–158 (2020).
Ponder, K. P. Immunology of neonatal gene transfer. Curr. Gene Ther. 7, 403–410 (2007).
Wilson, J. M. G. & Jungner, G. Principles and Practice of Screening for Disease. Public Health Papers No. 34 (World Health Organization, 1968).
Dobrow, M. J., Hagens, V., Chafe, R., Sullivan, T. & Rabeneck, L. Consolidated principles for screening based on a systematic review and consensus process. CMAJ 190, E422–E429 (2018).
Chien, Y. H. et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J. Pediatr. 190, 124–9.e1 (2017).
Kraszewski, J. N. et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet. Med. 20, 608–613 (2018).
Lin, Y. et al. Newborn screening for spinal muscular atrophy in China using DNA mass spectrometry. Front. Genet. 10, 1255 (2019).
Vill, K. et al. One year of newborn screening for SMA—results of a German pilot project. J. Neuromuscul. Dis. 6, 503–515 (2019).
Dangouloff, T., Vrščaj, E., Servais, L. & Osredkar, D., SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul. Disord. 31, 574–582 (2021).
Czibere, L. et al. High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR. Eur. J. Hum. Genet. 28, 23–30 (2020).
Dobrowolski, S. F. et al. Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling. Clin. Chem. 58, 1033–1039 (2012).
Phan, H. C., Taylor, J. L., Hannon, H. & Howell, R. Newborn screening for spinal muscular atrophy: snticipating an imminent need. Semin. Perinatol. 39, 217–229 (2015).
Shih, S. T., Farrar, M. A., Wiley, V. & Chambers, G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J. Neurol. Neurosurg. Psychiatry 92, 1296–1304 (2021).
D’Silva, A. M. et al. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme Dev. Med. Child Neurol. 64, 625–632 (2021).
Kariyawasam, D. S. T. et al. “We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. EClinicalMedicine 33, 100742 (2021).
Kariyawasam, D. S. T., Russell, J. S., Wiley, V., Alexander, I. E. & Farrar, M. A. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet. Med. 22, 557–565 (2020).
Boemer, F. et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci. Rep. 11, 19922 (2021).
Dangouloff, T., Burghes, A., Tizzano, E. F. & Servais, L., NBS SMA Study Group. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscul. Disord. 30, 93–103 (2020).
Kong, L. et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci. Transl. Med. 13, eabb6871 (2021).
Kay, D. M. et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet. Med. 22, 1296–1302 (2020).
McCandless, S. E. & Wright, E. J. Mandatory newborn screening in the United States: history, current status, and existential challenges. Birth Defects Res. 112, 350–366 (2020).
Prior, T. W. et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am. J. Hum. Genet. 85, 408–413 (2009).
